A Franceschino | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where A Franceschino is active.

Explore More

Publication

Featured researches published by A Franceschino.

Haematologica | 2008

Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.

A Franceschino; Lucia Tornaghi; Benemacher; Sarit Assouline; Carlo Gambacorti-Passerini

Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine kinase-phosphate correlation, cholesterol and triglyceride values.

Leukemia | 2005

Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph + chronic myeloid leukemia patients

Rocco Piazza; Vera Magistroni; F Andreoni; A Franceschino; Lucia Tornaghi; M Varella-Garcia; S Bungaro; Federica Colnaghi; Gianmarco Corneo; E Pogliani; Carlo Gambacorti-Passerini

Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients

Leukemia | 2005

Response to 'D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients' by Leguay et al

Rocco Piazza; Vera Magistroni; A Franceschino; Carlo Gambacorti-Passerini

Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by Leguay et al

Nature Medicine | 2007

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

Carlo Gambacorti; Lucia Tornaghi; A Franceschino; Rocco Piazza; Gianmarco Corneo; E Pogliani

Blood | 2007

Imatinib concentrations in human milk

Carlo Gambacorti-Passerini; Lucia Tornaghi; Elena Marangon; A Franceschino; Enrico Maria Pogliani; Maurizio D'Incalci; Massimo Zucchetti

Blood Cells Molecules and Diseases | 2006

The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.

Rocco Piazza; Vera Magistroni; A Franceschino; F Andreoni; Lucia Tornaghi; Federica Colnaghi; Gianmarco Corneo; E Pogliani; Carlo Gambacorti-Passerini

Haematologica | 2006

Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.

A Franceschino; Lucia Tornaghi; Rocco Piazza; E Pogliani; C Gambacorti Passerini

Blood | 2006

In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic

M Puttini; A Coluccia; F Boschelli; A Franceschino; L Tomaghi; Shaheen Ahmed; Sara Redaelli; Rocco Piazza; Magistroni; F Andreoni; Leonardo Scapozza; Franca Formelli; C Gambacorti Passerini

Nature Medicine | 2007